Synairgen inhaled interferon beta shows significant benefit in COVID-19

UK-based nano cap Synairgen (LON: SNG) (OTCPK:SYGGF) has been a star in Europe driven by the potential of its inhaled therapy for COVID-19.

Last week, shares rocketed 450% after the company announced preliminary data from a 101-subject Phase 2 study that showed treatment with nebulized interferon beta, licensed for use in multiple sclerosis, cut the risk of severe disease symptoms by 79% and reduced the average discharge time by 33%.

Despite the rally, the company still sports a very modest market cap of ~$69M.

https://seekingalpha.com/news/3595946-synairgen-inhaled-interferon-beta-shows-significant-benefit-in-covidminus-19